Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: Momelotinib vs Danazol in Myelofibrosis
NCT04173494Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Started Feb 2020; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT04173494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173494.